Trinity Biotech Receives WHO Approval for Offshore HIV Test Manufacturing

Trinity Biotech has received World Health Organization approval to offshore and outsource the upstream manufacturing of its TrinScreen HIV rapid test, a key diagnostic product in HIV screening programs. This regulatory milestone is central to the company’s strategic transformation plan aimed at improving financial performance and achieving sustainable profitability by shifting from in-house to a more scalable and cost-effective outsourced manufacturing model. The transition is expected to enhance gross margins, free up working capital, improve supply chain resilience, and reduce fixed costs, while maintaining product quality and regulatory compliance. CEO John Gillard emphasized that this move will unlock significant cost efficiencies, improve operational agility, and position the company for long-term financial health. Implementation of the new manufacturing model is planned for the third quarter of 2025. This initiative aligns with Trinity Biotech’s broader goals of streamlining operations and focusing internal resources on innovation and market expansion.